ProSomnus (ProSomnus) Notes Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Notes Receivable?

ProSomnus's Notes Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

ProSomnus Notes Receivable Historical Data

The historical data trend for ProSomnus's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Notes Receivable Chart

ProSomnus Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Notes Receivable

ProSomnus Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Notes Receivable	Get a 7-Day Free Trial								-	-	-	-	-

ProSomnus Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

ProSomnus Notes Receivable Related Terms

Thank you for viewing the detailed overview of ProSomnus's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ProSomnus (ProSomnus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

5675 Gibraltar Drive, Pleasanton, CA, USA, 94588

Website

https://www.prosomnus.com

ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.

Executives

Sung Kim	officer: Chief Technical Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens	10 percent owner	C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow	officer: Chief Financial Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp	10 percent owner	65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers	director	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak	director, officer: Chief Executive Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy	officer: Chief Growth Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc	10 percent owner	C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp	10 percent owner	505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge	director	7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073